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Abstract
Background: Hyperlipidemias are common and the last decades have seen substantially growing evidence of their
causative role in the development of atherosclerosis and subsequent cardiovascular diseases. Since hyperlipidemias
usually do not cause direct clinical symptoms, they often remain undiagnosed until a serious cardiovascular event
occurs. Especially for LDL-hypercholesteremia, there are well-established treatment options available to prevent the
occurrence of atherosclerosis. However, there is a lack of knowledge regarding the proper treatment of elderly
patients. The goal of this study was to assess the prevalence of hyperlipidemia in a group of young and a group of
elderly community-dwelling participants and to determine to what extent treatment of hyperlipidemia should be
initiated or required.
Methods: Crossectional data from a total of 2151 subjects (1657 in the elderly group, mean age 69, and 494 in the
young group (control group), mean age 29) of the Berlin Aging Study II (BASE-II) were available. Medical history was
assessed and recorded by trained physicians and prevalence of lipid disorders was determined with laboratory tests,
including a lipid-profile.
Results: A large proportion of subjects (39%) were unaware of an existing lipid disorder. The prevalence of
hyperlipidemia was more frequent in the elderly group (76%) compared to the young group (41%).
Hypercholesterolemia was the most common diagnosed disorder (64%), followed by hyperlipoproteinemia(a) (18%),
hypertriglyceridemia (7%) and combined hyperlipoproteinaemia (5%). Only a minority of this cohort was treated
with lipid-lowering medication (17%) and of those treatment targets according to ESC guidelines were reached
only in 16.5 %.
Conclusions: Hyperlipidemias appear underdiagnosed and undertreated. As the prevalence of these disorders
increases with age and with regard to their role as a major modifiable risk factor for cardiovascular disease it seems
to be advisable to aim for more consistent and sustainable screening and treatment of these common disorders.
Trial Registration: BASE-II registered with the clinical trial registry Deutsches Register Klinischer Studien
(DRKS00009277).
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Introduction
Hyperlipidemias are common and particularly LDL-
Hypercholesterolemia plays a causative role in the
pathogenesis of cardiovascular diseases such as coronary
heart disease and cerebro-vascular disease [1, 2]. The
most common hyperlipidemia are hypercholesterolemia,
hypertriglyceridemia, combined hyperlipoproteinaemia,
and hyperlipoproteinemia(a). Of those, hypercholesterol-
emia based on elevated LDL-cholesterol-levels is the best
analyzed and understood disease with the most effective
treatment options. Less data are available on the role of
hypertriglyceridemia, combined hyperlipoproteinaemia
and hyperlipoproteinemia(a) in the pathogenesis of car-
diovascular disease, therefore most recommendations
are less specific in these disorders and at the same time
treatment options are limited. It is generally accepted
that treatment of high cholesterol levels should be per-
formed based on risk stratification with assessment of
other co-existing risk factors including age, sex, smok-
ing, hypertension, diabetes or chronic kidney disease [3,
4]. Moreover, general consensus exists for treatment
with statins when coronary heart disease, stroke and per-
ipheral arterial disease already present to prevent athero-
sclerotic plaque progression and recurrent events.
Although it is unclear which treatment target levels
should specifically be achieved in old and very old pa-
tients (>80 years), it appears that patients in general
benefit rather from moderate to high-intensive statin
therapy compared to low-intensive statin therapy [4].
With regard to primary prevention (patients who do not
suffer from coronary heart disease, stroke and peripheral
arterial disease) it is recommended to treat patients in
certain risk groups such as patients with very high levels
of LDL-cholesterol (>190 mg/dL), coexisting diabetes
mellitus or with an intermediate or high 10-year risk to
suffer major cardiovascular events [5, 6].
The goal of this study was to assess the prevalence of
hyperlipidemia in a group of young (mean age 29 years)
and a group of elderly community-dwelling participants
(mean age 68 years) and to determine to what extent
treatment of hyperlipidemia should be initiated or
required.
Methods
Subjects were participants of the Berlin Aging Study II
(BASE-II), which comprises about 2.151 adult volunteers
from the Berlin metropolitan area [7]. The BASE-II
study and the participant recruitment have been de-
scribed in detail in previous publications [7, 8]. BASE-II
is a prospective epidemiological study aimed at the iden-
tification and characterization of factors associated with
“healthy” vs “unhealthy” ageing, broadly examining indi-
viduals in domains such as mental and physical health,
psychological functioning and social as well as economic
status. In short, eligibility criteria at the time of recruit-
ment were community-dwelling elderly subjects aged be-
tween 60 and 82 years for the elderly group. All
participants were examined by trained physicians who
assessed the medical history and the current and previ-
ous medication. In addition to recording disease states,
functional status was assessed with validated question-
naires and a comprehensive geriatric assessment. Com-
parisons with representative survey data from Berlin and
Germany revealed that BASE-II participants are charac-
terized by slightly higher education and better self-
reported health status than the general population of
Berlin and Germany [7].
Anthropometric measurements:
Body weight was measured in light clothes with a portable
electronic scale to the nearest 0.1 kg and height was deter-
mined to the nearest 0.1 cm by using an electronic weigh-
ing and measuring station (seca 764, seca, Hamburg,
Germany). Weight and height were used to calculate the
body mass index (BMI) (weight [kg]/height [m]2).
Functional tests:
Handgrip strength was assessed with a Smedley Dyna-
mometer (Scandidact, Denmark). The subjects were
instructed to perform a maximal isometric contraction,
the test was performed three times for each hand and
the highest value of either side was chosen.
Laboratory testing:
Total cholesterol, LDL-cholesterol, HDL-cholesterol and
triglycerides were measured via a homogeneous enzym-
atic colorimetric assay (Cobas®; Manufacturer: Roche
Diagnostics GmbH, Sandhafer Strasse 116, 68305 Mann-
heim; Germany)
Lipoprotein(a) was measured via a particle enhanced
immunoturbidimetric test. It uses a fixed time determin-
ation of the Lp(a) concentration by photometric measure-
ment of antigen-antibody-reaction between antibodies
against Lp(a) bound to particles and Lp(a) present in the
sample. (Cobas®; Manufacturer: Roche Diagnostics GmbH,
Sandhafer Strasse 116, 68305 Mannheim; Germany)
Criteria for lipid-disorders were (fasting measurement):
Hypercholesterolemia: total Cholesterol >= 5.2 mmol/L
(200 mg/dL) [9]
Combined hyperlipoproteinemia: total Cholesterol >=
5.2 mmol/L and triglycerides >= 2.28 mmol/L (200 mg/
dL) [10]
Low HDL Cholesterol: HDL Cholesterol <1.0 mmol/L
in men or <1.3 mmol/L in women [6]
Hypertriglyceridemia: Triglycerides >= 2.28 mmol/L
[10]
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Hyperlipoproteinemia(a): Lipoprotein(a) >= 50 mg/dL
[11].
Statistical analysis
In the current study cross-sectional data were used to
determine the prevalence of certain diseases in the two
BASE-II age groups. In addition, medians of laboratory
findings were compared. Data are presented as median
and inter quartile range (IQR). As laboratory findings
were not normally distributed Kolmogorov–Smirnov test
was used to compare differences between groups. To
compare prevalence/proportions the chi-square test was
used. Statistical analyses were conducted using IBM®
SPSS® Statistics Version 23. A critical alpha level (i.e., P-




The mean age of subjects was 29.0 ± 3.2 and 68.8 ± 3.7
years in the young age and the elderly group respect-
ively. The sex distribution was comparable in both
groups (53% female subjects in the young group, 51% fe-
male subjects in the elderly group).
The mean body mass index was 23.3 kg/m2 in the
young group and 26.9 kg/m2 in the elderly group, while
the mean waist circumference was 82 cm in the young
group and 96 cm in the elderly group (see Table 1). In
the elderly group 18% reported to have consulted an in-
ternist during the last three months, 60% had consulted
a general practitioner. In the young group 5% reported
to have consulted an internist during the last three
months, 35% had consulted a general practitioner.
Prevalence of diseases
Chronic diseases were more common in the elderly
group: Arterial hypertension was present in 73% of the
elderly group and in 15% of the young group. Diabetes
was diagnosed in 12% of subjects from the elderly group
and 0% in the young group. Chronic kidney disease
(GFR (glomerular filtration rate) <= 60mL/min/1.73m2 )
was present in 17% of the elderly group and 0% in the
young group, while a coronary heart disease or equiva-
lent (history of myocardial infarction, peripheral artery
disease or cerebrovascular disease) was known in 8% of
the elderly group and 0% in the young group. 31% of the
young group were current smokers and 19% former
smokers, while 9% of the elderly group were current
smokers and 43% former smokers.
Health Assessment
Elderly subjects showed comparable results to young
subjects in regard of self-assessment of general health,
while maximal handgrip strength was lower (34 vs. 38 kg
elderly vs. young group).
Hyperlipidemia
In regard of hyperlipidemia, only 3% of the young group
reported to have a known lipid disorder, while 37% of
the elderly group reported to have a lipid disorder.
The elderly group showed significantly higher levels of
total cholesterol, LDL cholesterol, triglycerides and lipo-
protein(a) compared to the young group (see Table 2).
Transferred to diagnoses the elderly group met signifi-
cantly more often the criteria for hypercholesterolemia,
hypertriglyceridemia, combined hyperlipoproteinemia,
and hyperlipoproteinemia(a) compared to the young
Table 1 Demographic data, prevalence of diseases, health assessment in both groups
Study Group Young Age Group Elderly Age Group
Total Number (n) or mean (SD) 494 1657
Age years mean (SD (standard deviation)) 29.0 (3.2) 68.8 (3.7)
Female 53.0% 51.4%
Arterial Hypertension (systolic BP >=140 mmHg and/or diastolic BP >=90 mmHg) 14.6% 72.7%
Diabetes 0.2% 11.5%
Current smoker 31.2% 9.3%
Body mass index (SD) kg/m2 23.3 (4.1) 26.9 (4.2)
Waist circumference cm (SD) 82 (12) 96 (12)
Chronic kidney disease (GFR <= 60mL/min/1.73m2) 0.0% 17.1%
Coronary heart disease or equivalent 0.0% 7.5%
Global Self-Assessment of Health Status “good” or “very good” 85.4% 71.6%
Self-Assessment of Health Status from the 36-Item Short Form Survey (SF-36) “good” or better - 85.5%
Global Self-Assessment of Satisfaction with Life (0= completely dissatisfied to 10= completely satisfied) (SD) 7.6 (1.3) 7.9 (1.5)
Right Hand Grip Strength (SD) kg 38.2 (10.1) 33.6 (9.7)
Abbreviations: BP: blood pressure, GFR: glomerular filtration rate, SD: standard deviation, SF-36: Self-Assessment of Health Status from the 36-Item Short
Form Survey
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group. There were no significant differences between
groups in regard of HDL-cholesterol (11.0% vs. 13.0%),
although there was the known significant difference be-
tween female and male subjects (females having higher
levels compared to males) seen similar in all groups
(young vs. elderly; untreated vs. treated).
Combined lipid disorders
In both groups elevated triglyzerides were found in about
two thirds combined with elevated LDL-cholesterol,
showing that elevated triglycerides commonly appear in
form of a combined hyperlipoproteinemia. 5% of subjects
with hyperlipoproteinemia(a) had co-existing hypertriglyc-
eridemia in both age groups. In regard of the coexistence
of hypercholesterolemia and hyperlipoproteinemia(a)
there was a difference between the age groups: while
73.0% of elderly subjects with a hyperlipoproteinemia(a)
had a co-existing hypercholesterolemia, only 43.1% of
young subjects with a hyperlipoproteinemia(a) had co-
existing hypercholesterolemia.
The combination of hypertriglyceridemia and Low
HDL cholesterol was present in 2.3% in the young group
and 3.1% in the elderly group.
Findings in relation to current guidelines
The European guidelines on prevention of cardiovascu-
lar disease in clinical practice (2016) define 4 different
risk groups for the risk to suffer a fatal cardiovascular
disease in the next 10 years (low risk, moderate risk,
high risk, very high risk) [2, 3]. The calculation of these
risk groups uses a formula which includes sex, age, mea-
sured blood pressure, measured cholesterol levels and
smoking status. It is based on large cohort studies with
cardiovascular events. The result of the formula is the
total 10-year risk of a fatal cardiovascular disease given
in percent [12]. 84% of the elderly group belonged to the
very high risk group to suffer a fatal cardiovascular
Table 2 Laboratory findings, prevalence of lipid disorder and treatments in both groups
Study Group Young Age Group Elderly Age Group P
Total Number (n) 494 1657
Reported Lipid Disorder 2.6% 37.1% <0.01
Laboratory findings
Total Cholesterol, median (IQR (interquartile range)), mmol/L 4.5 (4.0 – 5.1) 5.6 (4.9 – 6.3) <0.01
LDL-Cholesterol, median (IQR), mmol/L 2.5 (2.0 – 3.0) 3.4 (2.8 – 4.0) <0.01
HDL-Cholesterol, median (IQR),all, mmol/L 1.5 (1.3 – 1.8) 1.6 (1.3 – 1.9) 0.097










Lipoprotein(a), median (IQR), mg/dL 7.0 (1.5 – 21.0) 11.0 (4.6 – 33.9) <0.01
Triglycerides, median (IQR), mmol/L 0.9 (0.7 – 1.2) 1.1 (0.9 – 1.5) <0.01
Any measured Lipid Disorder 40.6% 76.0% <0.01
- Hypercholesterolemia (Total Cholesterol >= 5.2 mmol/L) 23.7% 64.0% <0.01
- Hypertriglyceridemia (Triglycerides >= 2.3 mmol/L) 3.5% 6.8% <0.01
- Combined Hyperlipoproteinaemia (Total Cholesterol >= 5.2 mmol/L and
Triglycerides >= 2.3 mmol/L)
2.6% 4.6% 0.054
- Hyperlipoproteinemia(a) (lipoprotein(a) >= 50 mg/dL) 7.9% 18.3% <0.01
- Low HDL Cholesterol (HDL Cholesterol <1.0 mmol/L in men or <1.3 mmol/
L in women), all
13.0% 11.0% 0.238
- Low HDL Cholesterol (HDL Cholesterol <1.0 mmol/L in men or <1.3 mmol/
L in women), by sex
female 11.6% male 14.5% female 9.8% male 12.3% 0.342/
0.107
- Combined Hypertriglyceridemia and Low HDL Cholesterol 2.3% 3.1% 0.356
Consultation of a general practitioner during the last 3 months 35.0% 60.3% <0.01
Treated with any lipid-lowering medication 0.0% 16.8% <0.01
- Statins 0.0% 16.3% <0.01
- Fibrates 0.0% 0.2% 0.274
- Ezetimibe 0.0% 1.1% 0.02
LDL-treated to target, ESC-Guidelines 97.6% 7.4% <0.01
Abbreviations: ESC: European Society of Cardiology, GFR: glomerular filtration rate, HDL: high density lipoprotein, IQR: interquartile range, LDL: low density
lipoprotein, Lp(a): Lipoprotein(a), SD: standard deviation
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disease in the next 10 years, 13% belonged to the high
risk group, and 3% to the moderate risk group (see
Figure 1). In the young group 99% belonged to the low
risk group and 1% to the high-risk group (mainly due to
obesity, hypertension, diabetes, and smoking).
The American College of Cardiology/American Heart
Association Guidelines on the Treatment of Blood Chol-
esterol to Reduce Atherosclerotic Cardiovascular Risk
takes a slightly different approach and defines “Statin
benefit groups” considering prevalent diseases including
diabetes, myocardial infarction or equivalent, and levels
of LDL-cholesterol [4]. The relevant conditions assigning
patients to “Statin benefit groups” are: 1. Prevalent ath-
erosclerotic cardiovascular disease or 2. Severe hyper-
cholesterolemia (LDL-C ≥4.9 mmol/L) or 3. Diabetes
mellitus or 4. An intermediate or higher risk (≥7.5%) for
atherosclerotic cardiovascular disease in patients in pri-
mary prevention. According to this 88% of the elderly
group belong to a statin benefit group, while 1% of the
young group belong to the statin benefit group (see Fig-
ure 2).
Lipid treatment and goals While none in the young
group was treated with lipid lowering medication, 17%
of the elderly group were on treatment. This treatment
consisted mainly of statins (16%) followed by ezetimibe
(1%) and fibrates (0.2%). Regarding the LDL treatment
targets, only 7% of the elderly group were treated to
target while 98% of the young group had LDL-levels at
target.
Subjects of the elderly group were divided in subjects
treated with lipid-lowering medication and subjects
without lipid lowering medication. Subjects on lipid-
lowering medication showed significantly lower levels of
total cholesterol, LDL-cholesterol and HDL-cholesterol
compared to subjects without treatment. At the same
time subjects on lipid-lowering medication showed sig-
nificantly higher levels of triglycerides and lipoprotein(a).
Subjects receiving lipid-lowering medication showed
higher prevalence of arterial hypertension, diabetes,
chronic kidney disease and coronary heart disease or
equivalent. At the same time participants receiving lipid-
lowering medication were more likely male than female
(58.4% vs. 46.6% in the non-treatment group). 17% of
the patients on treatment reached LDL-goals, while 6%
of the untreated patients had LDL-cholesterol levels at
goal (see Table 3).
Discussion
This study highlights that the prevalence of hyperlipid-
emia increases with age. Significant differences in levels
of lipid parameters and prevalence of hyperlipidemia
have been observed between the young and the elderly
group. The elderly group showed strikingly higher levels
of total cholesterol (mean difference 1.1 mmol/l) and
Fig. 1 Frequency of the 4 risk levels among subjects in both groups to suffer a fatal CVD (cardio vascular disease) in the next 10 years, defined in
the ESC/EAS (European Society of Cardiology/ European Atherosclerosis Society) Guidelines for the management of dyslipidaemia
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fulfilled far more often the diagnostic criteria of hyper-
cholesterolemia (64.0 vs. 23.7% old vs. young). There are
various proposed reasons accounting for these differ-
ences, i.e. higher lipid levels in older age, including the
age-associated loss of hepatic LDL receptors, higher
body-mass index, larger waist circumference and lower
sex hormone levels, among others [13–17]. For triglycer-
ides an association with diabetes and central obesity is
known, so hyperlipidemia in conjunction with these
health conditions have to be considered [18]. No signifi-
cant differences were found between the serum levels of
HDL-cholesterol in elderly and young subjects. As to
this, previous studies have been inconsistent: some pos-
tulated a negative correlation between age and HDL-
cholesterol levels, others found sex-differences in the
change of HDL-levels with age [19, 20]. Drugs such as
Fibrates or Niacin can raise HDL-levels, however an ef-
fect on cardiovascular endpoints or mortality wasn’t
shown by studies to date. To current knowledge increas-
ing HDL levels via pharmacological manipulation be-
yond optimal lipid lowering therapy for secondary
prevention is not beneficial [21]. Likely other factors in-
cluding smoking status, body-mass index and physical
activity are more relevant factors in regard of HDL-
cholesterol levels than age [22]. Lipoprotein(a) levels
were significantly higher in the elderly group compared
to the young group, although the majority in the elderly
group (82%) had lipoprotein(a)-levels below the cut-off
of 50 mg/d, above which Lp(a) is considered as an add-
itional factor that indicates a very high cardiovascular
risk. Intra-individually lipoprotein(a)-levels are relatively
constant across the lifespan but a correlation between
age, low sex hormone levels and high lipoprotein(a)-
levels has also been postulated before [23, 24]. In line
with this the findings of this study support the hypoth-
esis of an influence of sex hormone levels on lipopro-
tein(a)-levels, especially low estrogen levels correlate
with high LDL-cholesterol and Lipoprotein(a)-levels.
As expected, it has been observed that subjects treated
with lipid-lowering medication showed significantly
lower levels of total cholesterol, LDL-cholesterol and
HDL-cholesterol than those without treatment; at the
same time treated subjects showed higher levels of tri-
glycerides. Statins are the most commonly used lipid-
lowering drugs. Statins do not have a relevant influence
on triglycerides or lipoprotein(a). Presumably subjects
who receive a lipid-lowering treatment have more often
a combined hyperlipoproteinemia or an additional
Fig. 2 Frequency of belonging to the “Statin benefit group”, defined in the ACC/AHA Guidelines (American College of Cardiology/American Heart
Association) on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults compared in both groups
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hyperlipoproteinemia(a) than those who do not receive
any medication. Moreover it is known that high trigly-
ceride levels may mimic high total cholesterol levels, de-
pending on the laboratory method used. Therefore, it
can be assumed that these patients are being treated
more often compared to others. Applying the recom-
mendations of current guidelines for dyslipidemia, 88-
97% of this elderly group should be considered for a
drug treatment (primarily statins) [3, 4]. The treatment
with statins is considered to be effective in primary and
secondary prevention, reducing the relative risk in
cardio-vascular events in total by 20% [25–28]. Although
the guidelines call for a risk–benefit discussion between
the patient and physician before the initiation of statin
therapy, it remains unclear how this influences the gen-
eral therapeutic decision. Taking into account the rise of
cholesterol levels with age and the demographic change
a rising number of patients who, according to current
guidelines, meet the criteria for lipid lowering treatment
has to be expected [29, 30]. As elderly subjects show
20% higher cholesterol levels in mean compared to
young ones, a different cutoff value could be discussed.
At the same time, meeting the diagnostic criteria for hy-
percholesteremia is not equivalent for an urgent treat-
ment. The results show that (elderly) subjects are often
unaware of an existing dyslipidemia, as only 37% in the
elderly group reported dyslipidemia compared to 75%
with a measured dyslipidemia. This lack of awareness for
dyslipidemia has also been seen in previous studies [31].
The treatment gap is even larger as only 17% were on
active drug treatment, whereas 20% did not receive ac-
tive drug treatment though having known dyslipidemia.
The undertreatment of elderly patients with dyslipidemia
has been described in other studies [32–37]. The differ-
ence in frequencies of consulting a general practitioner
could be a reason (58.3% vs. 70.5%; untreated and
treated) had contact to a general practitioner in the last
3 month), although this does not explain the whole
difference.
If central obesity or diabetes are present there should
be an attempt to improve these conditions primarily be-
cause this could result in improved lipid levels. However
if this fails, and the conditions are on a stable, not im-
provable state, initiation of lipid-lowering treatment
should not be missed according to guidelines. Although
it is not known why these participants are not on any ac-
tive drug treatment, a lack of information can be hy-
pothesized. Further it can be expected that a majority
was never exposed to a statin treatment, so that side-
effects of a statin therapy may only have a subordinate
role. Including the fact that risk factors as arterial hyper-
tension, diabetes, chronic kidney disease, and coronary
heart disease are more prevalent in the elderly patient
group, it has to be considered that these patients are at
higher cardiovascular risk. Overall, the therapeutical gap
seems to be increasing with age.
Table 3 Laboratory findings in treated and untreated subjects of the elderly group
Study Group Not treated with any lipid-lowering
medication
Treated with any lipid-lowering
medication
P
Total Number (n)/Percentage (%) 1357 (83.2%) 273 (16.8%)
Male 46.6% 58.4 % <0.01
Current smoker 9.0% 10.8% 0.338
Consultation of a general practitioner during the last 3
months
58.3% 70.5% <0.01
Arterial Hypertension (systolic BP >=140 mmHg and/or
diastolic BP >=90 mmHg)
70.5% 83.2% <0.01
Diabetes mellitus 9.1% 22.9% <0.01
Chronic kidney disease (GFR <= 60mL/min/1,73m2) 6.7% 12.8% <0.01
Coronary heart disease or equivalent 4.2% 24.0% <0.01
Laboratory findings
Total cholesterol, median (IQR), mmol/L 5.7 (5.0 – 6.3) 4.8 (4.2 – 5.4) <0.01
LDL-Cholesterol, median (IQR), mmol/L 3.5 (2.9 – 4.1) 2.6 (2.1 – 3.2) <0.01
HDL-Cholesterol, median (IQR), all, mmol/L 1.6 (1.3 – 1.9) 1.5 (1.2 – 1.8) <0.01
HDL-Cholesterol, median (IQR), by sex, mmol/L female 1.8 (1.5–2.1) male1.4 (1.1-1.7) female 1.7 (1.4-2.0) male 1.4 (1.1-1.6) 0.04/ <0.16
Lipoprotein(a), median (IQR), mg/dL 11.0 (4.2 – 31.9) 11.0 (5.0 – 41.5) 0.163
Triglycerides, median (IQR), mmol/L 1.1 (0.8 – 1.5) 1.2 (0.9 – 1.7) <0.01
LDL-C at target, ESC-Guidelines 5.6% 16.5% <0.01
Abbreviations: BP: blood pressure, ESC: European Society of Cardiology, GFR: glomerular filtration rate, HDL: high density lipoprotein, IQR: interquartile range, LDL:
low density lipoprotein, Lp(a): Lipoprotein(a), SD: standard deviation
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However, the argument of a dispensable treatment in
context of polypharmacy and age remains a controversial
one. Regarding time to benefit statins seem to show
positive effects after 1-2 years of treatment, whereas at
the same time statins belong to intensively investigated
drugs, repeatedly proving effects on all-cause mortality
and major vascular events in secondary prevention [25,
38, 39]. In primary prevention the evidence is less clear
as to elderly patients: it seems that elderly patients with-
out previous vascular diseases may not profit from a
short treatment of 2-3 years [40–42]. At the same time
in most cited studies about 50% of included elderly pa-
tients had a history of vascular diseases, so that the pro-
portion of “real” primary prevention patients might be
significantly smaller compared to the young patient
group.
Waiving a lipid-treatment should be considered com-
parably to cases in which physicians waive a treatment
of arterial hypertension: multimorbid patients with a
short life expectancy who will most likely not reach the
point of benefit from a strict treatment to target strategy,
are more probe to side-effects and who already suffer
from serious functional limitations [43]. But with regard
to general health assessment and surrogates such as
handgrip strength this data do not suggest that a major-
ity of the elderly participants in this study are afflicted
by a generally impaired functional health status that
could support the lack of active drug treatment.
Our results are subject to limitations. Due to the
cross-sectional data structure statements about the dif-
ferences between the young and the elderly group have
to be handled with care.
It is unknown how differences between generations
(like attitude towards healthy nutrition, regular exercise)
affect lipid levels. Some of the differences might be at-
tributed to a less healthy attitude of the elderly gener-
ation and are not to be expected in this degree in the
young group in future. In addition, the effect of a lipid
lowering therapy in regard to the time and extend ath-
erosclerosis developed could vary individually. Although
some studies, show effects after two years of treatment
in elderly patients and theses patients are at highest risk
of developing a cardiovascular event. The initiation of a
lipid-lowering treatment could be too late to have a sig-
nificant effect in some patients. Since this study shows
clearly that the prevalence of dyslipidemias is generally
high and also considerably increased within aged per-
sons compared to younger persons, physicians should
screen aged persons for hyperlipidemia. Hypercholester-
olemia is usually a well controllable risk factor in regard
of end-organ damage associated with above-mentioned
diseases. Similar to arterial hypertension, which is a dis-
ease with an increased prevalence with age, physicians
should screen for hyperlipidemia and treat patients
based on clinical judgement and an individually patient-
centered approach as the treatment can reduce the oc-
currence of cardiovascular events even in elderly pa-
tients. Of course, geriatric aspects such as a potentially
higher rate of side effects, especially myalgia and myop-
athy with potentially can cause also functional limitation
and drug interactions in case of polypharmacy must be
regarded -In case of statin intolerance ezetimibe or
PCSK9 (proprotein convertase subtilisin/kexin type 9 )
inhibitors represent reasonable alternative treatment op-
tions. In the end it remains to the patients decision after
an information conversation with their treating doctor if
they accept to be on active treatment because of high




Hyperlipidemia is more prevalent in elderly patients
compared to young patients and appear to be under-
treated. As hyperlipidemia can be diagnosed and treated
effectively, and since treatment with statins reduces the
occurrence of cardiovascular events in total by up to
20%, treatment should not be withhold from patients
solely due to their age alone.
Future perspective
More information is needed in elderly patients to adjust
treatment options, and to select those with the highest
potential benefit of drug therapy.
Take home message
Physicians should screen elderly patients regularly for
hyperlipidemia and hyperlipidemia should be treated ac-
cording to guidelines and good clinical practice.
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